FI
MTNB icon

FormulaFolio Investments’s Matinas BioPharma MTNB Stock Holding History

FormulaFolio Investments’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-250
Closed -$10K – 678
2020
Q3 		$10K Buy
+250
New +$9.94K ﹤0.01% 315

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FormulaFolio Investments's MTNB Position: Q4 2020 in Review

FormulaFolio Investments sold out of Matinas BioPharma (MTNB) in Q4 2020, closing a stake of 250 shares — an estimated $10K sold.

FormulaFolio Investments first reported a position in MTNB in Q3 2020 and held it in 1 quarter. The position peaked at $10K in Q3 2020. 71 funds tracked by Wall St. Rank hold MTNB as of Q4 2020.

  • FormulaFolio Investments reported no remaining Matinas BioPharma position as of Q4 2020 after selling out during the quarter.
  • FormulaFolio Investments sold 250 Matinas BioPharma shares in Q4 2020, an estimated $10K.
  • FormulaFolio Investments first reported a position in Matinas BioPharma in Q3 2020 and held it in 1 quarter.
  • FormulaFolio Investments's Matinas BioPharma position peaked at $10K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2020.

Based on FormulaFolio Investments's 13F filing for Q4 2020, filed 2 Mar 2021.